

 	<b>Company name:</b> Qvanteq AG	<b>Founded:</b> 2009
	<b>Mission:</b> Providing quality of life for patients after stenting	
	<b>Industry:</b> Medical device	
	<b>Web site:</b> www.qvanteq.com	
	<b>Contact:</b> Arik Zucker (CEO), arik.zucker@qvanteq.com	


## THE COMPANY

Qvanteq AG develops novel bioactive coronary and endovascular stents to address and overcome clinical adverse effects of today’s devices. Qvanteq’s **BIOACTIVE Qstent** promises **fast** and **controlled** healing. This reduces the risk of restenosis (re-narrowing) and thrombosis while increasing patient’s quality of life by limiting the need for anti-coagulation medication to only 1 month.

Qvanteq AG is ISO 13485 certified and is held by private investors. The company is a spin-off from the Swiss Federal Institute of Technology (ETH), based at the Technopark in Zurich, Switzerland.

## THE PROBLEM – Today’s coronary stents in Pig coronary arteries 30 days post stenting

### Bare Metal Stent (BMS)




**Uncontrolled tissue growth**  
causing restenosis (re-narrowing)

**Insufficiently healed** stent segments increase thrombosis risk

- ▶ Prevention of thrombus by anti-coagulant medication / DAPT
- ▶ Results in increased bleeding risk for the patient

### Drug-Eluting Stent (DES)



## THE SOLUTION – The BIOACTIVE Qstent Coronary, combining the benefits of today’s stents



- ▶ Reduced thrombosis risk through fast and complete healing
- ▶ Reduced restenosis (re-narrowing)
- ▶ ONLY 1 month of anti-coagulant medication

### The Qstent

- ▶ showed superiority over main DES \*)
- ▶ currently in a European multi center First-in-Human clinical study
- ▶ CE market approval obtained, commercialization start in Europe in Q4 2015

Industry partner / investor for commercialization in China

## Qstent, the smart solution for quality of life

Qvanteq AG, Technoparkstr. 1, CH-8005 Zurich, Switzerland, Phone +41 500 98 90, [www.qvanteq.com](http://www.qvanteq.com)

### \*) Pre-clinical in-vivo study data:

- Performed at CBSET, Lexington MA, USA / 30 days in pig coronary arteries (Sus scrofa, Yorkshire)
- Qstent showed superiority over Xience (Abbott Vascular), Promus Element (Boston Scientific) and Resolute Integrity (Medtronic)

Supported by:



Partners

EPFL  
Innovation Park



ETH zürich

— GEBERT RÜF STIFTUNG —

VAUD



EY Entrepreneur  
Of The Year

swissnex  
China